Navigation Links
Keryx Biopharmaceuticals Inc. Regains Compliance With NASDAQ Listing Requirements
Date:6/17/2009

NEW YORK, June 17 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) announced today that the Company has received a letter from The NASDAQ Stock Market confirming that it has regained compliance with the minimum bid price requirement for continued listing on The NASDAQ Capital Market under Listing Rule 5550(a)(2) and that the matter is now closed.

The Company also received a letter from the NASDAQ Listing Qualifications Hearings Panel confirming that it has demonstrated a market value of listed securities over the required minimum of $35 million for 10 consecutive trading days, for continued listing on The NASDAQ Capital Market under Listing Rule 5550(b)(2), and that the Panel has determined to continue the listing of the Company's securities on The NASDAQ Stock Market.

The Company's stock continues to be listed on the NASDAQ Capital Market and its ticker symbol of KERX remains unchanged.

"We are pleased to have regained compliance with all the NASDAQ Capital Market listing requirements," stated Ron Bentsur, Chief Executive Officer of Keryx Biopharmaceuticals. "We believe this represents an important step in building value for our stockholders."

About Keryx Biopharmaceuticals, Inc.

Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important, novel pharmaceutical products for the treatment of life-threatening diseases, including renal disease and cancer. Keryx is developing Zerenex(TM)(ferric citrate), an oral, iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. Zerenex has recently completed a Phase 2 clinical program as a treatment for hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease. The Company is also developing KRX-0401 (perifosine), a novel, potentially first-in-class, oral anti-cancer agent that modulates Akt, a protein in the body associated with tumor survival and growth. KRX-0401 also modulates a number of other key signal transduction pathways, including the JNK and MAPK pathways, which are pathways associated with programmed cell death, cell growth, cell differentiation and cell survival. KRX-0401 is currently in Phase 2 clinical development for multiple tumor types. The Company also actively engages in business development activities that include seeking strategic relationships for its product candidates, as well as evaluating compounds and companies for in-licensing or acquisition. Keryx is headquartered in New York City.

Cautionary Statement

Some of the statements included in this press release may be forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Among the factors that could cause our actual results to differ materially are the following: There can be no assurance that the Company will be able to satisfy the listing requirements of The NASDAQ Capital Market in the future or that the Company's stock will not be affected by other risk factors identified from time to time in our reports filed with the Securities and Exchange Commission. Any forward-looking statements set forth in this press release speak only as of the date of this press release. We do not intend to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. This press release and prior releases are available at http://www.keryx.com. The information in our website is not incorporated by reference into this press release and is included as an inactive textual reference only.

    KERYX CONTACT:
    Lauren Fischer
    Director, Investor Relations
    Keryx Biopharmaceuticals, Inc.
    Tel: 212.531.5962
    E-mail: lfischer@keryx.com


'/>"/>
SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Keryx Biopharmaceuticals, Inc. Receives Extension for Nasdaq Listing Compliance
2. Keryx Biopharmaceuticals, Inc. Announces First Quarter 2009 Financial Results
3. Keryx Biopharmaceuticals, Inc. Requests an Appeal Hearing After Receiving Notice of Delisting From Nasdaq
4. Keryx Biopharmaceuticals Receives Nasdaq Notification
5. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2008 Financial Results
6. Keryx Biopharmaceuticals KRX-0401 (Perifosine) Data Selected for Oral Presentation at the 50th Annual Meeting of the American Society of Hematology
7. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2008 Financial Results on Tuesday, November 11, at 8:30 A.M. EST
8. Keryx Biopharmaceuticals, Inc. Announces Second Quarter 2008 Financial Results
9. Keryx Biopharmaceuticals, Inc. Announces Poster Presentations Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) to be Presented at the Upcoming American Society of Hematology Meeting in Atlanta, Georgia
10. Presentation Time Correction: Keryx Biopharmaceuticals Presents at 12:00pm, ET Tomorrow (Oct. 3) at William Blair & Company Small-Cap Growth Stock Conference
11. Johnson & Johnson Completes Tender Offer for Omrix Biopharmaceuticals, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/21/2017)... , ... January 21, 2017 , ... "ProDOF is the perfect set of tools for ... another subject in a scene," said Christina Austin - CEO of Pixel Film Studios. ... Easily create the illusion of a DSLR racking focus from one area into the ...
(Date:1/21/2017)... ... January 21, 2017 , ... Northern ... has recently joined their multi-specialty medical group. The dermatology practice provides general ... , “We’re excited to add this excellent dermatology practice to our group’s medical ...
(Date:1/20/2017)... ... January 20, 2017 , ... Spectrum Aquatics Launches New ADA Portable Motion Trek BP 300 Lift. ... lift is mounted on wheels, it can be wheeled out of the way and stored ... to the deck. "We have transformed the feedback from customers into specific enhancements and created ...
(Date:1/20/2017)... Boca Raton, FL (PRWEB) , ... January 20, 2017 , ... ... supplement development, announced it attended the January ECRM trade show to continue the marketing ... technologically advanced vitamin C supplement, known for providing 400 percent better absorption than traditional ...
(Date:1/20/2017)... ... January 20, 2017 , ... International Protein, a company based out ... announced it attended the January ECRM trade show in Hilton Head, SC. , ... was determined to create a line of products that would elevate her fitness regime. ...
Breaking Medicine News(10 mins):
(Date:1/20/2017)... , Jan. 20, 2017  Ethicon ... acquired Megadyne Medical Products, Inc., a privately ... and markets electrosurgical tools used in operating ... intelligence of Ethicon,s* advanced energy devices with ... a major step forward in Ethicon,s goal ...
(Date:1/20/2017)... Fla. , Jan. 20, 2017 Wells Specialty ... at 3796 Howell Branch Rd in Winter Park, ... Winter Park . Operations have been consolidated into ... Pharmacy is also pleased to announce that Chad Tomlinson ... President of the Company effective immediately. Mr. Tomlinson is a ...
(Date:1/19/2017)... Jan. 19, 2017 The global immunomodulators ... by 2025, according to a new study by ... to be predominantly driven by high R&D investments ... large-scale production of new and therapeutically advanced drugs. ... drugs at an unprecedented rate into the immunomodulators ...
Breaking Medicine Technology: